Expression Of Cyclin E,CDK2,P57 And CDC25A In Gastric Carcinomas

Objective: thoroughly investigate on the expression and clinical significance of the cell cycle regulatory factors like CyclinE, CDK2, p57 and CDC25A in gastric cancer, analyze the relationship between the expressions and clinicopathological features of CyclinE, CDK2, p57 and CDC25A in gastric carcinoma, research on the relativity among CyclinE, CDK2, p57 and CDC25A, and further prove the anomaly of those CyclinE, CDK2, p57 and CDC25A related to the cell cycle modification in the gastric carcinoma occurrence mechanism.Medium and Method: take 30 patients hospitalized in The Second Hospital of Hebei Medical University from June, 2004 to June, 2006, with 17 males and 13 females aging from 47 to 78, 58.7 year old in average. Among them, there are 14 patients in StageⅡ-Ⅲgroup, 9 in StageⅠ, and 7 in mucinous carcinoma group. 10 patients including 7 males and 3 females with an average age of 47.3 year old are diagnosed as benign lesions(like ulcer, trauma, perforation, etc. ) .No research objects have radiation therapy or chemotherapy before this medical examination. The samples are those tumor tissues excised in operations, 3cm adjacent tissues and normal stomach tissues. CyclinE, CDK2, p57 and CDC25A in the above samples are then detected with the Immunohistochemical streptavidin-perosidase method and analyzed comprehensively in combination with such clinicopathologic factors as differentiation degree and histological type.Survey Results: through observing immunohistochemical stained sections under light microscope, p57obvious-stained-cytoplasm cells are detected as normal stained. So do CDK2 obvious-stained-nucleus cells, CyclinE obvious-stained-nucleus cells and CDC25A stained-nuclear membrane cells. Those with discontinuous, obviously weakened or deletion staining are detected as abnormal stained ones. Based on the percentage of normal stained cells in the total tumor cells, the sections are judged in three grades: with 0～5%(-) Grade One, 6～50%(+) Grade Two and 51～100%(++) Grade Three.The ratio of positive manifestation of P57 in progressive gastric carcinomas specimens is 40%(12/30) and 73.3%(22/30) in the nearby 3cm; while in normal stomach tissues, the positive manifestation ratio is 90.0%(9/10), remarkably different ( P<0.05) from the former one. As for the ratio of positive manifestation of Cyclin E, it is 70%(21/30) in progressive gastric carcinomas specimens and 36.7%(11/30) in the nearby 3cm, distinctly discrepant ( P<0.05) with the ratio 10.0%(1/10) in the normal stomach tissue specimens. As for the ratio of positive manifestation of CDK2, it is 80%(24/30) in progressive gastric carcinomas specimens and 63.3%(19/30) in the nearby 3cm, distinctly discrepant ( P<0.05) with the ratio 10.0%(1/10) in the normal stomach tissue specimens. And for the positive manifestation ratio of CDC25A, it is 73.3%(22/30) in progressive gastric carcinomas specimens and 43.3%(13/30) in the nearby 3cm, in obvious contrast ( P<0.05)with 20.0%(2/10) in the normal ones. Moreover, the ratio of positive manifestation of Cyclin E is 78.6%(11/14) in StageⅡ-Ⅲgroup, 55.6%(5/9) in StageⅠgroup, and 71.4%(5/7) in mucinous carcinoma group, with little difference (P>0.05) among. The ratio of positive manifestation of CDK2 is 92.9%(13/14) in StageⅡ-Ⅲgroup, 77.8%(7/9) in StageⅠgroup and 85.7%(6/7) in mucinous carcinoma group, with little difference( P>0.05) among. The ratio of positive manifestation of P57 is 50.0%(7/14) in StageⅡ-Ⅲgroup, 44.4%(4/9) in StageⅠgroup and 71.4%(5/7) in mucinous carcinoma group, with little difference(P>0.05) among. The positive manifestation ratio of CDC25A is 85.7%(12/14) in StageⅡ-Ⅲgroup, 77.8%(7/9) in StageⅠgroup and 57.1%(4/7) in mucinous carcinoma group, with little difference(P>0.05) among. The positive manifestations of Cyclin E and CDC25A in the gastric carcinomas tissue specimens are in direct proportion(r=0.371,P<0.05), CDK2 and CDC25A in direct proportion as well(r=0.245,P<0.05), while those of p57 and CDC25A are in inverse proportion(r=-0.412,P<0.05), and P57and CyclinE in inverse proportion as well(r=-0.384,P<0.05).Conclusion: CyclinE, CDK2 and CDC25A probably promote the occurrence and development of gastric carcinoma, while p57 acts reversely, that is, possibly inhibits the occurrence and development of gastric cancer. However, no one may have influence on the differentiation degree of the tumor. CDC25A may have activation effect on CyclinE, while p57 may inhibit CyclinE. What's more, negative correlation is found between p57 and CDC25A, which indicates the possible inhibiting and inhibited relationship between them and is for further research and discussion.